Melanie Cole – Aird Berlis

Melanie is a member of the firm’s Capital Markets, Corporate/Commercial and Mergers & Acquisitions/Private Equity Groups as well as the Cannabis, Capital Pool Company and Mining Groups. Her practice focuses on a broad range of matters, including public and private offerings, private placement financings, reverse takeovers, flow-through financings, stock exchange listings, continuous disclosure, corporate governance and the formation and completion of qualifying transactions for companies established under the TSXV CPC Program. Melanie regularly advises both domestic and international clients, ranging from small start-ups to large public companies, including those listed on the TSX.Melanie represents the firm as a member of the Global Cannabis Partnership – an international initiative that focuses on the establishment of worldwide corporate social responsibility standards related to the production, marketing, public education, sale, after-sales service and informed consumption of legal cannabis.

Outside of her practice, Melanie is passionate about giving back to the community through her ongoing involvement in the charitable sector and by acting as a mentor to junior lawyers. In addition to being a member of the firm’s Associates Committee, Melanie serves as a Director of the Eating Disorders Foundation of Canada – a charity committed to raising funds to support evidence-based care for, research into and increased awareness about eating disorders in Canada. She is also Past Chair of the Breast Cancer Support Fund.

Prior to her legal career, Melanie was a legislative advisor to a federal Cabinet Minister.

Matters

• Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.
• Represented PsyBio Therapeutics, Inc., a biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders, in the completion of its reverse takeover of PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (TSXV:PSYB) and related private placement offering of subscription receipts for aggregate gross proceeds of $14.5 million.
• Represented Champignon Brands Inc., a ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer, in connection with its $15 million bought deal private placement.

Socials

• LinkedIn